Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy

R. C. Benson, J. H. Kinsey, D. A. Cortese, G. M. Farrow, D. C. Utz

Research output: Contribution to journalArticle

94 Scopus citations

Abstract

The demonstration that intravenously administered hematoporphyrin derivative concentrates preferentially in dysplastic and neoplastic transitional cells in the human bladder prompted a trial of hematoporphyrin derivative phototherapy in patients with transitional cell cancer of the bladder. A dose of 2.5 mg. per kg. was given intravenously 3 to 48 hours before treatment with light of a wavelength of 630 nm. from an argon ion pumped dye laser. Total light dose approximated 150 joules per cm.2. Four patients with resistant carcinoma in situ have been treated and all have had disappearance of the tumors proved by biopsy. Although there are many technical problems we believe that hematoporphyrin derivative phototherapy holds promise as an effective treatment modality, primarily for patients with resistant, recurrent in situ transitional cell carcinoma of the bladder.

Original languageEnglish (US)
Pages (from-to)1090-1094
Number of pages5
JournalJournal of Urology
Volume130
Issue number6
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy'. Together they form a unique fingerprint.

  • Cite this